Association between NQO1 C609T polymorphism and colorectal cancer risk

Tumor Biology

Volumn 34, Issue 6, 2013, Pages 4027-4032

  Wang, Yongbing ^a   Zhang, Genfu ^a   Luo, Yunbao ^a  

^a Shanghai Pudong New Area People s Hospital   (China)

Author keywords

Colorectal cancer; Meta analysis; NQO1; Polymorphism

Indexed keywords

REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE);

ARTICLE; ASIAN; CANCER RISK; CATALYSIS; CAUCASIAN; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME POLYMORPHISM; ETHNICITY; GENE FREQUENCY; GENETIC HETEROGENEITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84891493375     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0993-7     Document Type: Article

References (28)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Papagiorgis P: Colorectal cancer: Dichotomous or continuum model? Perhaps, a combination of both. Gut 2013
3. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011;6:479-507.
4. Stoffel EM, Chittenden A. Genetic testing for hereditary colorectal cancer: challenges in identifying, counseling, and managing high risk patients. Gastroenterology. 2010;139:1436-41. 1441 e1431.
5. Vasiliou V, Ross D, Nebert DW. Update of the NAD(P)H:quinone oxidoreductase (NQO) gene family. Hum Genomics. 2006;2:329-35.
6. Ross D, Siegel D. NAD(P)H:quinone oxidoreductase 1 (nqo1, dt-diaphorase), functions and pharmacogenetics. Methods Enzymol. 2004;382:115-44.
7. Guha N, Chang JS, Chokkalingam AP, Wiemels JL, Smith MT, Buffler PA. Nqo1 polymorphisms and de novo childhood leukemia: a huge review and meta-analysis. Am J Epidemiol. 2008;168:1221-32.
8. Siegel D, Yan C, Ross D. NAD(P)H:quinone oxidoreductase 1 (nqo1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol. 2012;83:1033-40.
9. van der Logt EM, Bergevoet SM, Roelofs HM, Te Morsche RH, Dijk Y, Wobbes T, et al. Role of epoxide hydrolase, Nad(P)H:quinone oxidoreductase, cytochrome p450 2e1 or alcohol dehydrogenase genotypes in susceptibility to colorectal cancer. Mutat Res. 2006;593:39-49.
10. Harth V, Donat S, Ko Y, Abel J, Vetter H, Bruning T. NAD(P)H quinone oxidoreductase 1 codon 609 polymorphism and its association to colorectal cancer. Arch Toxicol. 2000;73:528-31.
11. Hamajima N, Matsuo K, Iwata H, Shinoda M, Yamamura Y, Kato T, et al. NAD(P)H:quinone oxidoreductase 1 (nqo1) c609t polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol. 2002;7:103-8.
12. Sachse C, Smith G, Wilkie MJ, Barrett JH, Waxman R, Sullivan F, et al. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis. 2002;23:1839-49.
13. Dai E, Lu Z, Shi J, Yu Y, Zhang J. The Nad(P)H:quinone oxidoreductase 1 gene polymorphism and its association with colorectal cancer. Chin J Clin Oncol. 2004;31:89-91.
14. Begleiter A, Hewitt D, Maksymiuk AW, Ross DA, Bird RP. A Nad(P)H:quinone oxidoreductase 1 polymorphism is a risk factor for human colon cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:2422-6.
15. Hlavata I, Vrana D, Smerhovsky Z, Pardini B, Naccarati A, Vodicka P, et al. Association between exposure-relevant polymorphisms in cyp1b1, ephx1, nqo1, gstm1, gstp1, and gstt1 and risk of colorectal cancer in a Czech population. Oncol Rep. 2010;24:1347-53.
16. Nisa H, Kono S, Yin G, Toyomura K, Nagano J, Mibu R, et al. Cigarette smoking, genetic polymorphisms, and colorectal cancer risk: the Fukuoka colorectal cancer study. BMC Cancer. 2010;10:274.
17. Peng X, Jiang Y, Shi X, Hu Z, Zheng X. Relationship between nqo1 c609t gene polymorphism and risk of colorectal cancer. CHIN J PUBLIC HEALTH. 2010;26:1078-82.
18. Sameer AS, Shah ZA, Syeed N, Rasool R, Afroze D, Siddiqi MA. NAD(P)H:quinone oxidoreductase 1 (nqo1) pro187ser polymorphism and colorectal cancer predisposition in the ethnic Kashmiri population. Asian Pac J Cancer Prev. 2010;11:209-13.
19. Su XL, Yan MR, Yang L. Nqo1 c609t polymorphism correlated to colon cancer risk in farmers from western region of inner Mongolia. Chin J Cancer Res. 2012;24:317-22.
20. Peng XE, Jiang YY, Shi XS, Hu ZJ. Nqo1 609c > t polymorphism interaction with tobacco smoking and alcohol drinking increases colorectal cancer risk in a Chinese population. Gene. 2013;521:105-10.
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
22. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.
25. Wang YH, Lee YH, Tseng PT, Shen CH, Chiou HY. Human Nad(P)H:quinone oxidoreductase 1 (nqo1) and sulfotransferase 1a1 (sult1a1) polymorphisms and urothelial cancer risk in Taiwan. J Cancer Res Clin Oncol. 2008;134:203-9.
26. Fu J, Chen BC. Relationship between genetic polymorphism of nqo1 and susceptibility to bladder cancer. J Chin Oncol. 2012;18:561-4.
27. Misra V, Grondin A, Klamut HJ, Rauth AM. Assessment of the relationship between genotypic status of a dt-diaphorase point mutation and enzymatic activity. Br J Cancer. 2000;83:998-1002.
28. Siegel D, McGuinness SM, Winski SL, Ross D. Genotype-phenotype relationships in studies of a polymorphism in Nad(P)H:quinone oxidoreductase 1. Pharmacogenet. 1999;9:113-21.